Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risdiplam in Pediatric Patients With SMA After Gene Therapy
NCT05861999Phase 4Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2024
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 4 trial of risdiplam in spinal muscular atrophy (SMA), sponsored by Roche. Started Aug 2024; status: active, not recruiting.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT05861999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861999.